-
Published 9/23/2026
Hughes JA, Brooks KM, Fairlie L, Best BM, Mirochnick M, Hesseling AC, Decloedt E, Pinilla M, Shapiro DE, Eke AC. Letter Reply to "Mind the Postpartum Trough: Closing the Clofazimine Exposure Gap After Delivery in Rifampicin-Resistant Tuberculosis". J Infect Dis. 2026 Sep 23; 234(3):e747-e748. PMID: 42149552.
-
Published 9/1/2026
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson PL, Myer L, Celum C, Heffron R, Coleman J, Davey DLJ, Zhang L, von Kleist M, Hendrix CW, Momper JD, Bies R, Scott RK. Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum. J Clin Pharmacol. 2026 Sep; 66(9):e70278. PMID: 42687587.
-
Published 8/21/2026
Barr EA, Pinilla M, Momper JD, Eke AC, Koech L, Brooks KM, Ndyanabangi V, Burchett SK, Valiyaparambil S, Mirochnick M, Stek AM, Best BM, Jeffrey R, Stotz C, Van Schalkwyk M, Browning R, Shapiro DE, Powis KM. Breastmilk transfer and infant exposure to atazanavir/ritonavir in breastfeeding women with HIV: results from IMPAACT 2026. Front Reprod Health. 2026; 8:1892081. PMID: 42666560.
-
Published 1/17/2026
Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS, Stek A, Best BM, Mirochnick M, Wiesner L, George K, Knowles K, Browning R, DeYampert T, Hesseling AC, Decloedt E, Shapiro DE, Eke AC. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. J Infect Dis. 2026 Jan 17; 233(1):16-26. PMID: 41165222.
-
Published 1/1/2026
Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, Arora P, Cressey TR, Brooks KM, Best BM, Capparelli EV, Momper JD. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. J Clin Pharmacol. 2026 Jan; 66(1):e70134. PMID: 41405169.